| Title |
US FDA Modernization Act, Section 114
|
|---|---|
| Published in |
PharmacoEconomics, September 2012
|
| DOI | 10.2165/11590510-000000000-00000 |
| Pubmed ID | |
| Authors |
Peter J. Neumann, Pei-Jung Lin, Tom E. Hughes |
| Abstract |
Section 114 of the 1997 US FDA Modernization Act (FDAMA) is an important vehicle for pharmaceutical companies to promote the economic value of their drugs to formulary decision makers, but little is known about how the Section has been interpreted and used. |
Mendeley readers
The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | 6% |
| Unknown | 16 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 29% |
| Student > Master | 3 | 18% |
| Other | 1 | 6% |
| Lecturer | 1 | 6% |
| Student > Bachelor | 1 | 6% |
| Other | 3 | 18% |
| Unknown | 3 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Economics, Econometrics and Finance | 4 | 24% |
| Medicine and Dentistry | 4 | 24% |
| Nursing and Health Professions | 3 | 18% |
| Computer Science | 1 | 6% |
| Social Sciences | 1 | 6% |
| Other | 1 | 6% |
| Unknown | 3 | 18% |